SynthesisSystematic reviews2012
Effectiveness of rifaximin and fluoroquinolones in preventing travelers' diarrhea (TD): a systematic review and meta-analysis.
Synthesis in Systematic reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- Bismuth subsalicylate, probiotics, rifaximin and vaccines for the prevention of travelers' diarrhea: a systematic review and network meta-analysis.Frontiers in pharmacology · 2024Pooled it
- ACG Clinical Guideline: Diagnosis, Treatment, and Prevention of Acute Diarrheal Infections in Adults.The American journal of gastroenterology · 2016Guideline
- A New Criterion for Fluoroquinolone-Associated Disability Diagnosis: Functional Gastrointestinal Disorders.Medicina (Kaunas, Lithuania) · 2021Article
- Management of Acute Diarrheal Illness During Deployment: A Deployment Health Guideline and Expert Panel Report.Military medicine · 2017Article
- Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.Journal of travel medicine · 2017Review
- Review: chronic and persistent diarrhea with a focus in the returning traveler.Tropical diseases, travel medicine and vaccines · 2017Review
- Traveler's Diarrhea.The Medical clinics of North America · 2016Review
- Summary of the Committee to Advise on Tropical Medicine and Travel (CATMAT) Statement on Travellers' Diarrhea.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2015Article
- Perceived risk of watery diarrhea and dysentery and intended compliance with chemoprophylaxis among a deployed military population.Tropical diseases, travel medicine and vaccines · 2015Article
- Expatriates: special considerations in pretravel preparation.Current infectious disease reports · 2013Article
- Postinfectious functional gastrointestinal disorders: a focus on epidemiology and research agendas.Gastroenterology & hepatology · 2013Article
- Travelers' diarrhea: Clinical practice guidelines for pharmacists.Canadian pharmacists journal : CPJ = Revue des pharmaciens du Canada : RPCArticle
- Gastrointestinal Prophylaxis in Sports Medicine.Sports healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRecent developments related to a safe and effective nonabsorbable antibiotic, rifaximin, and identification of postinfectious irritable bowel syndrome as a frequent sequela call for a need to reconsider the value of primary prevention of traveler's diarrhea (TD) with antibiotics.
methodsRandomized, placebo-controlled, double-blind studies evaluating the effectiveness and safety of rifaximin or a fluoroquinolone chemoprophylaxis against TD were pooled using a random effects model and assessed for heterogeneity.
resultsThe nine studies (four rifaximin and five fluoroquinolone) included resulted in pooled relative risk estimates of 0.33 (95% CI = 0.24-0.45, I2 = 3.1%) and 0.12 (95% CI = 0.07-0.20, I2 =0.0%), respectively. Similar rates of treatment emergent adverse events were found between antibiotic and placebo groups.
conclusionsThis meta-analysis supports the effectiveness of antibiotics in preventing TD. However, further studies that include prevention of secondary chronic health outcomes among travelers to different geographic regions, and a formal risk-benefit analysis for antibiotic chemoprophylaxis, are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.